Investigación en enfermedades infecciosas

Carratalà, Jordi; Alcamí, José; Cordero, Elisa; Miró, José M.; Ramos, José Manuel

doi:10.1016/S0213-005X(08)76599-6

Información del artículo

Resumen

Bibliografía

Descargar PDF

Estadísticas

En los últimos años, la actividad investigadora en enfermedades infecciosas en España ha experimentado un impulso importante. La Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) acoge actualmente en su seno a 10 grupos de estudio en los que cooperan infectólogos y microbiólogos de distintos centros y que mantienen una actividad investigadora significativa. El programa de Redes Temáticas de Investigación Cooperativa en Salud ha constituido un marco apropiado para la coordinación estratégica de grupos de investigadores de distintas comunidades autónomas. La Red Española para la Investigación en Patología Infecciosa (REIPI) y la Red de Investigación en Sida (RIS) se han consolidado como plataformas que integran investigadores en enfermedades infecciosas de distintos grupos y que llevan a cabo regularmente proyectos de investigación de notable envergadura. La existencia en nuestro país de diversos modelos experimentales en patología infecciosa en instituciones de distintas comunidades autónomas supone un activo importante. Un análisis de la producción científica reciente en enfermedades infecciosas muestra que España ocupa un buen lugar en el contexto de la Unión Europea. La actividad investigadora en enfermedades infecciosas realizada en nuestro país representa una magnífica oportunidad para la formación de especialistas en esta área de conocimiento.

Palabras clave:

Enfermedades infecciosas

Investigación

Redes de Investigación

Sida

Modelos experimentales

Producción científica

There has been a significant increase in research activity into infectious diseases in Spain in the last few years. The Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) currently has ten study groups, with the cooperation of infectious diseases specialists and microbiologists from different centres, with significant research activity. The program of Redes Temáticas de Investigación Cooperativa en Salud (Special Topics Cooperative Health Research Networks) is an appropriate framework for the strategic coordination of research groups from the Spanish autonomous communities. The Spanish Network for Research in Infectious Diseases (REIPI) and the Network for Research in AIDS (RIS) integrate investigators in Infectious Diseases from multiple groups, which continuously perform important research projects. Research using different experimental models in infectious diseases, in numerous institutions, is an important activity in our country. The analysis of the recent scientific production in Infectious Diseases shows that Spain has a good position in the context of the European Union. The research activity in Infectious Diseases carried out in our country is a great opportunity for the training of specialists in this area of knowledge.

Key words:

Infectious Diseases

Investigation

Research Networks

AIDS

Experimental models

Scientific production

El Texto completo está disponible en PDF

Bibliografía

[1.]

H. Varmus.

Retroviruses.

Science, 240 (1998), pp. 1427-1435

[2.]

R.C. Gallo.

History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2.

Oncogene, 24 (2005), pp. 5926-5930

http://dx.doi.org/10.1038/sj.onc.1208980 | Medline

[3.]

Centers for Disease Control and Prevention.

Pneumocystis pneumoniae-Los Angeles.

Morbid Mortal Wkly Rep, 30 (1981), pp. 250-252

[4.]

F. Barré-Sinoussi, J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, et al.

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Science, 220 (1983), pp. 868-871

Medline

[5.]

J. Silberner.

AIDS blood screen approved.

Sci News, 127 (1985), pp. 48

[6.]

S. Wain-Hobson, P. Sonigo, O. Danos, S. Cole, M. Alizon.

Nucleotide sequence of the AIDS virus, LAV.

Cell, 40 (1985), pp. 9-17

Medline

[7.]

R. Pomerantz, D. Horn.

Twenty years of therapy for HIV-1 infection.

Nat Med, 9 (2003), pp. 867-873

http://dx.doi.org/10.1038/nm0703-867 | Medline

[8.]

E.M. Connor, R.S. Sperling, R. Gelber, P. Kiselev, G. Scott, M.J. O'Sullivan, et al.

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

N Engl J Med, 331 (1994), pp. 1173-1180

http://dx.doi.org/10.1056/NEJM199411033311801 | Medline

[9.]

J.W. Mellors, A. Muñoz, J.V. Giorgi, J.B. Margolick, C.J. Tassoni, P. Gupta, et al.

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Ann Intern Med, 126 (1997), pp. 946-954

Medline

[10.]

X. Wei, S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, P. Deutsch, et al.

Viral dynamics in human immunodeficiency virus type 1 infection.

Nature, 373 (1995), pp. 117-122

http://dx.doi.org/10.1038/373117a0 | Medline

[11.]

Y. Feng, C.C. Broder, P.E. Kennedy, E.A. Berger.

HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Science, 272 (1996), pp. 872-877

Medline

[12.]

T. Dragic, V. Litwin, G.P. Allaway, S.R. Martin, Y. Huang, K.A. Nagashima, et al.

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CCCKR-5.

Nature, 381 (1996), pp. 667-673

http://dx.doi.org/10.1038/381667a0 | Medline

[13.]

A.M. Caro-Murillo, J. Castilla, S. Pérez-Hoyos, J.M. Miró, D. Podzamczer, R. Rubio, et al.

Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results.

Enferm Infecc Microbiol Clin, 25 (2007), pp. 23-31

Medline

[14.]

Handbook of animal models of infection,

[15.]

García de la María., F. Marco, J.M. Miro, The Hospital Clinic Experimental Endocarditis Study Group.

Modelling systems in bacterial disease: What do they tell us?.

Eur Infect Dis, 2 (2008), pp. 2-5

[16.]

J.L. Mainardi, L. Gutmann, J. Acar, F. Goldstein.

Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis.

Antimicrob Agent Chemother, 39 (1995), pp. 1984-1987

[17.]

J. Gavaldà, C. Torres, C. Tenorio, P. López, M. Zaragoza, J.A. Capdevila, et al.

Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides.

Antimicrob Agents Chemother, 43 (1999), pp. 639-646

Medline

[18.]

J. Gavaldá, O. Len, J.M. Miró, P. Muñoz, M. Montejo, A. Alarcón, et al.

Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.

Ann Intern Med, 146 (2007), pp. 574-579

Medline

[19.]

J. Gavaldá, P.L. Onrubia, M.T. Gómez, X. Gomis, J.L. Ramírez, O. Len, et al.

Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides.

J Antimicrob Chemother, 52 (2003), pp. 514-517

http://dx.doi.org/10.1093/jac/dkg360 | Medline

[20.]

L.M. Baddour, W.R. Wilson, A.S. Bayer, V.G. Fowler Jr, A.F. Bolger, M.E. Levison, et al.

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Circulation, 111 (2005), pp. e394-e434

http://dx.doi.org/10.1161/CIRCULATIONAHA.105.165564 | Medline

[21.]

Modelos experimentales en patología infecciosa. Fundación Dr. Antonio Esteve,

[22.]

S. Edberg.

The measurement of antibiotics in human body fluids: techniques and signifigance.

Antibiotics in laboratory medicine,

[23.]

J. Gavalda, P.J. Cardona, B. Almirante, J.A. Capdevila, M. Laguarda, L. Pou, et al.

Treatment of experimental endocarditis due to Enterococcus faecalis using once daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum.

Antimicrob Agents Chemother, 40 (1996), pp. 173-178

Medline

[24.]

J.M. Miro, C. García de la Mària, Y. Armero, E. De Lazzari, D. Soy, A. Moreno, et al.

Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.

Antimcrob Agents Chemother, 51 (2007), pp. 2373-2377

[25.]

F. Marco, C. García de la Mària, Y. Armero, E. Amat, D. Soy, A. Moreno, et al.

Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Antimicrob Agents Chemother, 52 (2008), pp. 2538-2543

http://dx.doi.org/10.1128/AAC.00510-07 | Medline

[26.]

J. Martinez-Lacasa, C. Cabellos, A. Martos, A. Fernández, F. Tubau, P.F. Viladrich, et al.

Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis.

J Antimicrob Chemother, 49 (2002), pp. 507-513

Medline

[27.]

M.J. Rodríguez-Hernández, J. Pachón, C. Pichardo, L. Cuberos, J. Ibáñez-Martínez, A. García-Curiel, et al.

Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia.

J Antimicrob Chemother, 45 (2000), pp. 493-501

Medline

[28.]

A. Domenech, S. Ribes, C. Cabellos, M.A. Domínguez, A. Montero, J. Linares, et al.

A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections.

Microb Drug Resist, 10 (2004), pp. 346-353

http://dx.doi.org/10.1089/mdr.2004.10.346 | Medline

[29.]

J.A. Capdevila, J. Gavaldà, J. Fortea, P. López, M.T. Martin, X. Gomis, et al.

Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibioticlock technique.

Clin Microbiol Infect, 7 (2001), pp. 206-212

[30.]

P.J. Cardona, I. Amat, S. Gordillo, V. Arcos, E. Guirado, J. Diaz, et al.

Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.

Vaccine, 23 (2005), pp. 1393-1398

http://dx.doi.org/10.1016/j.vaccine.2004.09.008 | Medline

[31.]

J. Gavaldà, M.T. Martín, P. López, X. Gomis, J.L. Ramírez, D. Rodríguez, et al.

Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis.

Antimicrob Agents Chemother, 49 (2005), pp. 3028-3030

http://dx.doi.org/10.1128/AAC.49.7.3028-3030.2005 | Medline

[32.]

J. Joseph, N. Saubi, E. Pezzat, J.M. Gatell.

Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.

Expert Rev Vaccines, 5 (2006), pp. 827-838

http://dx.doi.org/10.1586/14760584.5.6.827 | Medline

[33.]

R.E. Gagnon, A.J. Macnab, F.A. Gagnon.

A quantitative ranking of Canada's research output of original human studies for the decade 1989 to 1998.

Can Med Ass J, 162 (2000), pp. 37-40

[34.]

L. Heffer, C. Tempfer, C. Kainz.

Geography of biomedical publications in the European Union, 1990-98.

Lancet, 353 (1999), pp. 1856

http://dx.doi.org/10.1016/S0140-6736(99)01278-7 | Medline

[35.]

J.M. Ramos-Rincón, M.M. Masía, F. Gutiérrez.

Producción científica en España en enfermedades infecciosas (1991-2001): posición en el contexto de la Unión Europea.

Enferm Infecc Microbiol Clin, 22 (2004), pp. 22-28

Medline

[36.]

Institute for Scientific Information Web of Knowledge. Disponible en: www.isinet.com

[37.]

Word Development Indicators 2006. Disponible en: http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20899413∼pa gePK:64133150∼piPK:64133175∼theSitePK:239419,00.htmls

Indexada en:

Síguenos:

Suscribirse:

Indexada en:

Síguenos:

Suscribirse:

Suscríbase a la newsletter